- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03244982
Fluorescein Angiography With a Full-dose Versus a Half-dose of Intravenous Fluorescein
Comparison of Timing and Image Quality of Different Phases of Optos Fluorescein Angiography Between Two Doses of Intravenous Fluorescein: 250mg Versus 500mg
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fluorescein angiography is a common procedure used in ophthalmology to diagnose and monitor diseases of the retinal and choroidal blood vessels. The most commonly seen adverse reactions to fluorescein angiography include nausea, vomiting, and urticaria. More severe reactions such as anaphylaxis are rare, occurring in only 1 of 2247 patients (0.4%) in a recent retrospective study. The standard dose of intravenous fluorescein used for fluorescein angiography is 500mg given intravenously in a 10% or 25% solution. One study from 2008 attempted to compare a 200mg dose versus a 500mg dose of intravenous fluorescein, and found that 200mg produced inferior image quality. However, the quality of the cameras used for fluorescein angiography has improved significantly in the last 10 years, and the scanning laser ophthalmoscope currently used for fluorescein angiography in our clinic (Optos) is significantly more effective than the fundus camera used in the 2008 study (Topcon). The scanning laser ophthalmoscope uses a fundamentally different imaging technique than the traditional fundus camera, with a much narrower illumination source, and has been shown to be significantly more sensitive in the detection of retinal vascular leakage.
A commonly used method for preventing adverse reactions in patients who have previously had an adverse reaction to intravenous fluorescein is to use a 250mg dose instead of the standard 500mg dose, despite the lack of evidence to this effect. In our anecdotal experience, a 250mg dose of intravenous fluorescein, used in patients whom have previously experienced an adverse reaction, has produced images of equivalent quality to the images produced using a full 500mg dose. To our knowledge, no study has compared a 500mg dose of intravenous fluorescein with a lower dose since the 2008 study previously mentioned, despite the advances in camera quality.
The study will aim to recruit a sample size of approximately 100 patients. Adult patients scheduled for fluorescein angiography at the Kresge Eye Institute will be recruited into the study by one of the study members if they meet inclusion and exclusion criteria. Once a patient has consented to participate in the study, they will be randomized to receive either a 250mg or 500mg dose of intravenous fluorescein with their fluorescein angiography procedure. All fluorescein angiograms will be done only if clinically indicated, and therefore the patient will not be placed at any increased risk by participating in this study. If a participant returns for a repeat fluorescein angiogram within the next four months, they will receive the dose (250mg or 500mg) which they did not receive with their previous angiogram. Patients who experience an adverse reaction during their first angiogram will be removed from the study in order to prevent a patient who had an adverse reaction with a half-dose from receiving a full-dose with a subsequent procedure. The photographer will adjust the image brightness settings in order to create the "best possible" image for each patient, and there will be no change between procedures with the 250mg and 500mg doses. A single camera (Optos) will be used for each patient in the study.
Data collection will be obtained from the patient, the imaging procedure, and the patient's electronic medical records at the Kresge Eye Institute. Information to be collected includes age, gender, race, visual acuity, and ophthalmologic medical history. The timing and quality of images at different phases of fluorescein angiography will be compared between 500mg and 250mg doses in each eye using objective and subjective measures. Subjective criteria will include grading of the images by a panel of masked retinal surgeons and residents. Grading will look at specific factors of a fluorescein angiography such as macula detail, macrovasculature, and microvasculature. These subjective criteria will then be used to determine whether any appreciable difference exists in the image quality between 250mg and 500mg doses of intravenous fluorescein given prior to Optos fluorescein angiography.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Kresge Eye Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients scheduled for fluorescein angiography at Kresge Eye Institute.
Exclusion Criteria:
- Patients with known major profusion defects on fluorescein angiography.
- Patients with prior adverse reactions to fluorescein angiography.
- Patients with significant photophobia as judged by the photographer.
- Patients with visually significant cataracts.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Full-Dose
Participants in this arm will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time, prior to their fluorescein angiogram.
If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time.
|
Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
Other Names:
Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
Other Names:
|
Experimental: Half-Dose
Participants in this arm will receive Fluorescein Na 10% Inj 250mg pushed over several seconds one time, prior to their fluorescein angiogram.
If they return for a second (clinically indicated) angiogram, they will receive Fluorescein Na 10% Inj 500mg pushed over several seconds one time.
|
Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
Other Names:
Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective comparison of image quality between full-dose and half-dose fluorescein angiography performed on the same patient.
Time Frame: Six months.
|
Participants who receive two clinically-indicated fluorescein angiography procedures within the time frame of the study will receive both doses of Fluorescein Na (250mg and 500mg).
These two images will then be compared to each other in terms of image quality by a team of masked retinal surgeons.
|
Six months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjective comparison of image quality between full-dose and half-dose fluorescein angiography among all patients enrolled in the study.
Time Frame: One month.
|
All of the images obtained during the patient recruitment phase of the study will be evaluated subjectively in terms of image quality by a panel of masked retinal surgeons.
The images will then be compared between patients to determine if there is a subjective difference in image quality between a 250mg and 500mg dose.
|
One month.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gary W Abrams, MD, Kresge Eye Institute
Publications and helpful links
General Publications
- Xu K, Tzankova V, Li C, Sharma S. Intravenous fluorescein angiography-associated adverse reactions. Can J Ophthalmol. 2016 Oct;51(5):321-325. doi: 10.1016/j.jcjo.2016.03.015. Epub 2016 Sep 3.
- Moosbrugger KA, Sheidow TG. Evaluation of the side effects and image quality during fluorescein angiography comparing 2 mL and 5 mL sodium fluorescein. Can J Ophthalmol. 2008 Oct;43(5):571-5. doi: 10.3129/i08-122.
- Nicholson BP, Nigam D, Miller D, Agron E, Dalal M, Jacobs-El N, da Rocha Lima B, Cunningham D, Nussenblatt R, Sen HN. Comparison of wide-field fluorescein angiography and 9-field montage angiography in uveitis. Am J Ophthalmol. 2014 Mar;157(3):673-7. doi: 10.1016/j.ajo.2013.12.005. Epub 2013 Dec 7.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 23897543
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fluorescein Angiography
-
Topcon CorporationCompletedFluorescein Angiography ImagingUnited States
-
Topcon Medical Systems, Inc.CompletedMedical Need for Fluorescein Angiography ImagingUnited States
-
Topcon CorporationCompletedRetina Condition Followed by Fluorescein Angiography ImagingUnited States
-
Southern California College of Optometry at Marshall...CompletedContact Lens-induced Corneal Fluorescein StainingUnited States
-
National Taiwan University HospitalUnknownMagnetic Resonance Angiography | Angiography, Digital SubtractionTaiwan
-
Changhai HospitalRecruiting
-
Huashan HospitalNot yet recruiting
-
Hillel Yaffe Medical CenterUnknown
-
Cardiovascular Associates of the Delaware ValleyAccessClosure, Inc.Completed
Clinical Trials on Fluorescein Na 10% Inj 500mg
-
Eye & ENT Hospital of Fudan UniversityUnknownNasopharyngeal Carcinoma | Squamous Cell Carcinoma of the Head and NeckChina
-
Dong-A ST Co., Ltd.CompletedHealthyKorea, Republic of
-
Dong-A ST Co., Ltd.CompletedHealthyKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType2 Diabetes MellitusKorea, Republic of
-
Cecilia CalvoThe Cleveland ClinicCompleted
-
Dr. Ofir Harnoy MDWithdrawnBowel EndometriosisIsrael
-
SK Plasma Co., Ltd.CompletedImmune ThrombocytopeniaKorea, Republic of
-
Boehringer IngelheimCompleted
-
Kang Stem Biotech Co., Ltd.RecruitingSafety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD) (smart(FURIN))Dermatitis, AtopicKorea, Republic of
-
Cedars-Sinai Medical CenterJohns Hopkins University; University of Alabama at Birmingham; University of... and other collaboratorsCompleted